AstraZeneca Plc said on Thursday its asthma treatment for a chronic inflammatory disease of the nasal passage linings, or sinuses, met main goals in a late-stage study.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,